First Description of KPC-2-Producing Klebsiella oxytoca Isolated from a Pediatric Patient with Nosocomial Pneumonia in Venezuela

Table 1

Antibiotic susceptibility patterns of K. oxytoca LMM-SA26, E. coli LMM-SA26Tc transconjugant, and E. coli MKD135 recipient.

Antibiotics tested	MIC (mg/liter) for
	K. oxytoca LMM-SA26	E. coli LMM-SA26Tc	E. coli MKD135
Cefotaxime	32	16	0.064
Cefotaxime/clavulanic acid^a	8	4	0.125
Ceftazidime	>256	125	0.025
Ceftazidime/clavulanic acid^a	32	8	0.25
Aztreonam	8	4	0.25
Imipenem	8	4	0.064
Ertapenem	>64	16	0.032
Meropenem	16	16	0.064
Gentamicin	>64	2	0.5
Amikacin	64	2	0.5
Tobramycin	16	1	0.125
Nalidixic Acid	1	0.064	1
Ciprofloxacin	2	0.125	0.25
Colistin	1	0.25	0.25
Tigecycline	0.25	0.125	0.125
Others test
DDST	+	+	−
MHT	+	+	−
Ertapenem + boronic acid^b	+	+	−
Imipenem + EDTA^c	−	−	−

Clavulanate was used at a fixed concentration of 4 mg/liter. ^bThe test was considered positive when boronic acid exhibited inhibitory effects increasing the bacterial growth-inhibitory zone to ≥5 mm around the ertapenem disk. ^cThe test was considered negative when EDTA did not increase the bacterial growth-inhibitory zone (≥5 mm) around the imipenem disk. DDST: double disk synergy test; MHT: modified Hodge test.